Xenon Stock Analysis

XENE -  USA Stock  

USD 26.00  0.29  1.10%

Xenon Pharmaceuticals price dip over the last few months may raise some interest from shareholders as it is trading at a share price of 26.00 on 778,779 in trading volume. The company directors and management were not very successful in positioning the company resources to exploit market volatility in December. However, diversifying your holdings with Xenon Pharmaceuticals or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.8. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Xenon Pharmaceuticals partners.
Check out Your Current Watchlist.

Xenon Stock Analysis 

 
Refresh
The Xenon Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Xenon Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Xenon Stock analysis module also helps to analyze the Xenon Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Xenon Stock Analysis Notes

About 70.0% of the company outstanding shares are owned by institutional investors. The book value of Xenon Pharmaceuticals was at this time reported as 5.87. The company recorded a loss per share of 1.55. Xenon Pharmaceuticals had not issued any dividends in recent years. Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company was incorporated in 1996 and is headquartered in Burnaby, Canada. Xenon Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 123 people. For more information please call Simon Pimstone at 604 484 3300 or visit https://www.xenon-pharma.com.

Xenon Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Xenon Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Xenon Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Xenon Pharmaceuticals generated a negative expected return over the last 90 days
Xenon Pharmaceuticals has high historical volatility and very poor performance
Xenon Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 19.85 M. Net Loss for the year was (65.64 M) with loss before overhead, payroll, taxes, and interest of (18.36 M).
Xenon Pharmaceuticals currently holds about 249.62 M in cash with (61.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.74.
Roughly 70.0% of the company outstanding shares are owned by institutional investors
Latest headline from www.marketbeat.com: FY2025 EPS Estimates for Xenon Pharmaceuticals Inc. Cut by Analyst - MarketBeat

Xenon Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Xenon Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Xenon Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report14th of March 2017
Next Earnings Report9th of May 2017
Next Fiscal Quarter End31st of December 2016
Next Fiscal Year End14th of March 2017
Last Quarter Report30th of September 2016
Last Earning Announcement31st of December 2015

Xenon Largest EPS Surprises

Earnings surprises can significantly impact Xenon Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2017-11-07
2017-09-30-0.39-0.43-0.0410 
2019-05-07
2019-03-31-0.37-0.42-0.0513 
2021-03-01
2020-12-31-0.4-0.340.0615 
View All Earnings Estimates

Xenon Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.34 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Xenon Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Xenon Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (18.09) % which means that it has lost $18.09 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (30.46) %, meaning that it created substantial loss on money invested by shareholders. Xenon Pharmaceuticals management efficiency ratios could be used to measure how well xenon pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 26th of January, Xenon Pharmaceuticals maintains the mean deviation of 2.78, and Market Risk Adjusted Performance of (0.13). Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Xenon Pharmaceuticals, as well as the relationship between them. Specifically, you can use this information to find out if the company will indeed mirror its model of past data patterns, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Xenon Pharmaceuticals, which can be compared to its rivals. Please check out Xenon Pharmaceuticals variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and semi variance to decide if Xenon Pharmaceuticals is priced fairly, providing market reflects its latest price of 26.0 per share. Given that Xenon Pharmaceuticals has jensen alpha of (0.09), we strongly advise you to confirm Xenon Pharmaceuticals's prevalent market performance to make sure the company can sustain itself at a future point.

Xenon Pharmaceuticals Price Movement Analysis

The output start index for this execution was one with a total number of output elements of sixty. The Simple Moving Average indicator is calculated by adding the closing price of Xenon Pharmaceuticals for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Xenon Pharmaceuticals short-term fluctuations and highlight longer-term trends or cycles. View also all equity analysis or get more info about simple moving average overlap studies indicator.

Xenon Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Xenon Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Xenon Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Xenon Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kenney Christopher John few days ago via Macroaxis 
Purchase by Kenney Christopher John of 700 shares of Xenon Pharmaceuticals
Mohammad Azab over a month ago via Macroaxis 
Exercise or conversion by Mohammad Azab of 3086 shares of Xenon Pharmaceuticals subject to Rule 16b-3
Gary Patou over a month ago via Macroaxis 
Exercise or conversion by Gary Patou of 2057 shares of Xenon Pharmaceuticals subject to Rule 16b-3
Von Seggern Christopher over a month ago via Macroaxis 
Purchase by Von Seggern Christopher of 4000 shares of Xenon Pharmaceuticals
Simon Pimstone over two months ago via Macroaxis 
Sale by Simon Pimstone of 17557 shares of Xenon Pharmaceuticals
Aulin Sherry over three months ago via Macroaxis 
Xenon Pharmaceuticals exotic insider transaction detected
Kenney Christopher John over three months ago via Macroaxis 
Acquisition by Kenney Christopher John of 150000 shares of Xenon Pharmaceuticals subject to Rule 16b-3
Gary Patou over six months ago via Macroaxis 
Acquisition by Gary Patou of 10000 shares of Xenon Pharmaceuticals subject to Rule 16b-3
Aulin Sherry over six months ago via Macroaxis 
Acquisition by Aulin Sherry of 100000 shares of Xenon Pharmaceuticals subject to Rule 16b-3
Robin Sherrington over six months ago via Macroaxis 
Exercise or conversion by Robin Sherrington of 13374 shares of Xenon Pharmaceuticals subject to Rule 16b-3
Simon Pimstone over six months ago via Macroaxis 
Exercise or conversion by Simon Pimstone of 22633 shares of Xenon Pharmaceuticals subject to Rule 16b-3
Michael Hayden over six months ago via Macroaxis 
Exercise or conversion by Michael Hayden of 3500 shares of Xenon Pharmaceuticals subject to Rule 16b-3

Xenon Pharmaceuticals Technical and Predictive Indicators

Xenon Pharmaceuticals Forecast Models

Xenon Pharmaceuticals time-series forecasting models is one of many Xenon Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Xenon Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Xenon Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Xenon Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Xenon shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Xenon Pharmaceuticals. By using and applying Xenon Stock analysis, traders can create a robust methodology for identifying Xenon entry and exit points for their positions.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company was incorporated in 1996 and is headquartered in Burnaby, Canada. Xenon Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 123 people.

Current Xenon Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Xenon analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Xenon analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
17.0Strong Buy3Odds
Xenon Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Xenon analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Xenon stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Xenon Pharmaceuticals, talking to its executives and customers, or listening to Xenon conference calls.
Xenon Analyst Advice Details

Xenon Stock Analysis Indicators

Xenon Pharmaceuticals stock analysis indicators help investors evaluate how Xenon Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Xenon Pharmaceuticals shares will generate the highest return on investment. By understating and applying Xenon Pharmaceuticals stock analysis, traders can identify Xenon Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio19.67
Fifty Two Week Low13.98
Revenue Growth24.00%
Shares Short Prior Month1.81M
Average Daily Volume Last 10 Day646.71k
Average Daily Volume In Three Month508.89k
Shares Percent Shares Out4.12%
Gross Margins-245.30%
Short Percent Of Float4.20%
Forward Price Earnings-13.54
Float Shares44.54M
Fifty Two Week High36.42
Enterprise Value To Ebitda-20.23
Fifty Day Average29.00
Two Hundred Day Average22.58
Enterprise Value To Revenue67.51
Check out Your Current Watchlist. Note that the Xenon Pharmaceuticals information on this page should be used as a complementary analysis to other Xenon Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Xenon Stock analysis

When running Xenon Pharmaceuticals price analysis, check to measure Xenon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xenon Pharmaceuticals is operating at the current time. Most of Xenon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xenon Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Xenon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xenon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Is Xenon Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenon Pharmaceuticals. If investors know Xenon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Xenon Pharmaceuticals is measured differently than its book value, which is the value of Xenon that is recorded on the company's balance sheet. Investors also form their own opinion of Xenon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Xenon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Xenon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Xenon Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.